| About Us | |
Pluromed, Inc., Woburn, Massachusetts, founded in 2003, is an early-stage medical technology company pioneering the use of injectable plugs to improve the safety, efficacy and economics of medical interventions. The Company develops, manufactures and markets a family of disposable medical devices and its core competencies lie in its proprietary polymer technology, the manufacturing of these polymers, and a robust understanding of their clinical applications due in part to its outstanding medical advisory board. Pluromed’s core strategy is targeted at the use of its devices to control bleeding during surgery. These products address a broad surgery market that includes cardiac and vascular surgery, prostate, kidney and liver surgery, plastic reconstructive surgery and trauma/battlefield applications. A secondary strategy is the use of these devices in the treatment of kidney stones. The products are based on the Company’s patented rapid reverse thermosensitive polymer technology. The polymers are liquid at low temperature and quickly transition to a high viscosity gel at body temperature.
|
|
Jean-Marie Vogel, Chief Executive Officer Previously Mr. Vogel was co-founder and CEO of Cryoma Laboratories, founder and Chairman of BioSphere Medical (NASDAQ:BSMD) and CEO of BioSepra, Inc. (NASDAQ:BSEP). Earlier he held international executive positions for Cuno, Inc., and Millipore Corporation. He holds an engineering degree from Ecole Centrale de Paris. |
|
James Wilkie, Vice President Operations Mr. Wilkie has 23 years of experience in medical device development. He has led device development teams at C.R. Bard and MedChem Products, and was President of Surgical Sealants, Inc. His expertise in device development and manufacturing has resulted in the commercialization of numerous successful products. He holds a BS in Engineering from the University of Massachusetts. |
|
John A. Merhige, Vice President Market Development Mr. Merhige has extensive business development, marketing and business management experience and has managed multi-million dollar business units for Fortune 500 companies. He holds a BA, BE in Mechanical Engineering and a Master of Engineering Management, all from Dartmouth College. |
|
John M. Barberich, Director Mr. Barberich has extensive experience in the life science industry and has completed many financing, licensing and related transactions. His experience includes serving as Chief Financial Officer, Treasurer and Secretary of ACADIA Pharmaceuticals, Scriptgen Pharmaceuticals (now Anadys) and Omrix Biopharmaceuticals. Mr. Barberich received his Master of Professional Accountancy degree from Georgia State University and his Bachelor of Science degree in Finance, with highest distinction, from The Pennsylvania State University. |
|
George W. Holbrook, Jr., Director Mr. Holbrook is the Managing Partner of Bradley Resources Company, a private investment and venture capital firm, which organizes and finances ventures in technology, medical devices and natural resource and power plant development. He is a former director of Thoratec (Nasdaq: THOR) and currently serves as a director of several private companies and as trustee of several charitable organizations. He received a B. S. Degree in Mechanical Engineering from Cornell University. |
|
Donald C. Freeman, Jr., Ph.D., Director Dr. Freeman is the former President/CEO of HydroCision, Inc., Chairman, CEO and Director of RadioMed Corporation, and President/CEO of multiple other medical device companies. He is currently on the board of directors of PhotoBioChem, SemiNex, Medical Record Bank, Electrolyzer Corporation and Pluromed. He holds an ScB Degree from Brown and a PhD in chemistry from the University of Maryland, and did post-doctoral research in physics at Duke. |
|
Alexander Schwarz, PhD, Director & Co-Founder Dr. Schwarz was previously Director of Research for BioSphere Medical. Dr. Schwarz is an expert in polymer-tissue interactions and has authored 27 publications, holds 8 patents and 6 patent applications. Previous medical device and drug development experience was obtained at Baxter Healthcare Corporation and BioSepra. He holds a PhD in Biochemical Engineering, magna cum laude, from the University of Bonn, Germany. |
|
